2023 U.S.-Booked Air Volume: $40.2 million
Primary Airline Suppliers: American, Delta, United
Primary Hotel Suppliers: Courtyard by Marriott, Marriott, Westin
Primary Car Rental Suppliers: Enterprise
Global Online Booking Tool: SAP Concur
Global Expense Supplier: SAP Concur
Global Payment Supplier: American Express
Global Risk Management Provider: ISOS
Consolidated Global TMC: Amex GBT

Pharmaceutical giant GSK has ramped up travel just as the company embarked on a full return-to-office strategy. At $40.2 million, U.S.-booked air volume in 2023 was up by more than 25 percent over the prior year. 

Yet 2023 was still early in a new organizational structure for the company, a year after it spun off its consumer business, which operates independently as Haleon. As such, last year the company didn’t know what to expect in terms of its travel volume baseline.

On the policy front, GSK added accessibility, sustainability and other changes to clarify the understanding of broader concepts. The company does not expect travel ever to return to pre-pandemic levels, and it has reduced travel strategically to achieve a reduction in scope 3 GHG emissions by 80 percent by 2030 as compared to 2020 as a baseline year. GSK aims to reduce absolute scope 1 and 2 emissions by 80 percent in the same timeframe.

The company uses a hybrid work setup called “performance by choice.” U.K.-based GSK reported group revenue of £30.3 billion in 2023, up from £29.3 billion in 2022. As of 2023, GSK had 70,200 employees with operations in more than 75 countries, including 37 manufacturing sites and four global research and development centers.